Member Info for Energyshares

Update on AVA6000 Phase 1a Clinical Trial Progress.

Presenter/Authors

U. Banerji, N. Cook, A. Anthoney, R. Plummer, W. D. Tap, J. T. R. Evans, L. D. Cranmer, C. Plummer, P. Loadman, G. Lahu, H. S. Jones, N. Kinnersley, F. McLaughlin, C.

Or Trolls

This is a statement from 2018

On the collaboration with Tufts talking about TMac, could they be ready to partner at an early stage for TMac knowing how well Pre/Cision works now.

“We believe that this new drug conjugate platform is transformational for the business. From our initial discussions with several large pharmaceutical companies, it is clear that there is significant interest and there is certainly the potential for partnering at an early stage once we have the appropriate supporting data from the collaboration with Professor Bachovchin.”

https://www.labmate-online.com/news/news-and-views/5/avacta-group/collaboration-to-develop-novel-class-of-drug-conjugate/46762

Courtesy of gggg21 on X

AVA7000 & AVA7500

https://synapse.patsnap.com/target/34d84f7e2cdd39e98653d20cf3a9d84e

https://www.ipo.gov.uk/p-pj/p-pj-ukappfiled?startYear=2023&startMonth=March&startDay=29th+-+6984&endYear=2024&endMonth=March&endDay=27th+-+7036&filter=avacta&perPage=50&sort=Publication+Date

That was wynbore

Markets don’t see it that way.

They are reacting like they need change .

Everyone believes in the science but if you have an incompetent CEO you need to change.

What are you worried about your just a paid troll

Sad 🤡

Please explain why you trashed the SP

for II money that is not coming in.

We need answers for your incompetence over the last month.

Leave Gardiner playing with his abacus and start taking responsibility for your actions.

You need to calm the markets and show them some commercialisation soon.

Christina Coughlin a breath of fresh air

Sack Michael Vinegrad group communications director for 9 years and 10 months and give her his wages,she has done more in a few months than he has in nearly 10 years.

Christina Coughlin tweet:

Welcome to the R&D Spotlight Series. We will take you in each episode into a deeper dive of our research a development activity at Avacta. Episode one: pre|CISION and how it works.

#LetsDoThis

#PeptidesCreateHope

Https://avacta.wistia.com/medias/1h18nhz59w

Yo shushi

Read the transcript below the video

It says AACI

👍

On the tweet transcript

Ellen states:

“We will be updating on this compound at the AACI in San Diego in early April.”

It’s the AACR in San Diego in April not AACI.

The AACI conference 2024 AACI/CCAF Annual Meeting, October 20-22, at Loews Chicago.

But AACI Abstract requirements dates:

February 1, 2024
Online submission tool opens

March 4, 2024 - 5:00 pm Pacific time
Deadline to submit abstracts

April 2024
Abstracts selected for oral presentation; notifications sent to submitting authors

Could Avacta submitting another poster in October.

Twitter

Ophidian

“Once the Pfizer takeover of Seagen is all cleaned up, the the Seagen warhead MMAE (that #AVCT have mentioned a few times before) can be popped on to pre|CISION.

I suspect the takeover screwed up timing on this before”

Myles

💯this.

I would hope only a delay, not a pulling out, as the new exec team goes over the fine details and checks SeaGen's DD on Avacta and pre | CISION, before getting approval of the Pfizer board.

Assuming of course we're actually on the money with SeaGen being the possible partner for Avacta!

B2HS2L

Here is tweet transcript below

https://avacta.wistia.com/medias/1h18nhz59w

“ We're highly encouraged by the early data being produced in our lead compound, and we're looking forward to those new cyotoxics, on the precision platform that will be in our pipeline soon.“

(new cyotoxics) not talking about AVA6k

Could this be a hint of a LD 😉

CJ

They are the 2 quotes I picked up from the tweet.

Like telling the trolls to FO

Update at AACR

Dox is Dox

“ And we cleave in such a way that we release doxorubicin exactly as normal doxorubicin. So it's now able to do what doxorubicin does, which is go into cells, and kill them.”

“ So AVA6000 has been through a phase 1 clinical trial. Reported in December, we've had a favourable safety profile and have seen improvement in toxicities compared to doxorubicin. And this has been in mild, toxicities as well as more severe events. We've also seen preliminary evidence for efficacy. We will be updating on this compound at the AACI in San Diego in early April.”

Dogs are back

Some major networking sessions at the AACR.

OCE experts will take part Regulatory Science and Policy (RSP) sessions, held in the San Diego Convention Center, Upper Level, Room 1, as well as other events listed below. Times are listed as Pacific Time.

https://www.fda.gov/about-fda/oncology-center-excellence/oce-public-

“I can't believe there are still some here that believe AS had any input in the level of the raise.”

He is the CEO ffs

He agreed for raise now instead of months ago.

He agreed to 34% discount which city boys jumped on and drove the raise down to 50p

Wynbore FO my thread

Smith & Gardiner have got a couple of months to save their jobs.

If this SP hasn’t recovered by the AGM they are gone.

I think Gardiner has gone anyway, he is out of his depth and has got Stifel taking the pi55 out of him.

Smith back on the tools in the Lab.

That placing was the unforgivable….

Still No apology.